Garg Ashwani, Leitzel Kim, Ali Suhail, Lipton Allan
Penn State Hershey Medical Center, 500 University Drive, Hershey, PA, 17033, USA,
Curr Osteoporos Rep. 2015 Apr;13(2):73-7. doi: 10.1007/s11914-014-0252-x.
Cancer treatment-induced bone loss treatment has an important role to prevent bone loss-related events like fracture, significant morbidity, mortality, disfigurement and loss of self-esteem, and health-care expenditure. Numerous factors, including treatment regimens and bone metastasis, increase the risk of osteoporosis or local bone destruction in most breast and prostate cancer patients. Cytotoxic chemotherapies, radiation, and hormonal therapies can lead to premature menopause and decrease bone mineral density. Over 60 % of breast cancer patients within 1 year of beginning postoperative adjuvant chemotherapy experience ovarian failure. Also, ovarian ablation and aromatase inhibitors used to treat breast cancer and orchiectomy and androgen deprivation therapy (ADT; to treat prostate cancer) cause substantial bone loss. In this article, we will focus mainly on antiresorptive therapy in the management of cancer treatment-induced bone loss (CTIBL). An understanding of CTIBL is critical for determining how to assess the risk and identify which patients may benefit from preventive therapy.
癌症治疗引起的骨质流失治疗对于预防与骨质流失相关的事件（如骨折、严重发病、死亡、毁容和自尊丧失以及医疗保健支出）具有重要作用。许多因素，包括治疗方案和骨转移，会增加大多数乳腺癌和前列腺癌患者患骨质疏松症或局部骨质破坏的风险。细胞毒性化疗、放疗和激素疗法可导致过早绝经并降低骨密度。超过60%的乳腺癌患者在开始术后辅助化疗的1年内会出现卵巢功能衰竭。此外，用于治疗乳腺癌的卵巢切除和芳香化酶抑制剂以及用于治疗前列腺癌的睾丸切除术和雄激素剥夺疗法（ADT）会导致大量骨质流失。在本文中，我们将主要关注抗吸收疗法在癌症治疗引起的骨质流失（CTIBL）管理中的应用。了解CTIBL对于确定如何评估风险以及识别哪些患者可能从预防性治疗中获益至关重要。
